Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1976 Oct;125(4):277–288.

Orofacial Dyskinesia

Clinical Features, Mechanisms and Drug Therapy

Ronald M Kobayashi 1
PMCID: PMC1237309  PMID: 23611

Abstract

Orofacial or tardive dyskinesias are involuntary repetitive movements of the mouth and face. In most cases, they occur in older psychotic patients who are in institutions and in whom long-term treatment with antipsychotic drugs of the phenothiazine and butyrophenone groups is being carried out. These dyskinesias are frequent in occurrence and characteristically are irreversible. Several biochemical mechanisms have been proposed as causes, including hypersensitivity or partially deneverated brain dopamine receptors and low affinity of the offending drugs for brain muscarinic cholinergic receptors. Clinical therapy has been attempted primarily with drugs that antagonize dopamine receptors or deplete brain dopamine. The benefits of drug treatment have been variable and lack of consistent improvement has been discouraging. Early recognition of dyskinesia should be attempted, and the dose reduced or the drug omitted at the first sign.

Full text

PDF
277

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AYD F. J., Jr A survey of drug-induced extrapyramidal reactions. JAMA. 1961 Mar 25;175:1054–1060. doi: 10.1001/jama.1961.03040120016004. [DOI] [PubMed] [Google Scholar]
  2. Altrocchi P. H. Spontaneous oral-facial dyskinesia. Arch Neurol. 1972 Jun;26(6):506–512. doi: 10.1001/archneur.1972.00490120046004. [DOI] [PubMed] [Google Scholar]
  3. BRANDRUP E. Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca. Am J Psychiatry. 1961 Dec;118:551–552. doi: 10.1176/ajp.118.6.551. [DOI] [PubMed] [Google Scholar]
  4. Baldessarini R. J., Lipinski J. F., Chace K. V. Effects of amantadine hydrochloride on catecholamine metabolism in the brain of the rat. Biochem Pharmacol. 1972 Jan;21(1):77–87. doi: 10.1016/0006-2952(72)90252-3. [DOI] [PubMed] [Google Scholar]
  5. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J. 1969 Dec 27;101(13):59–68. [PMC free article] [PubMed] [Google Scholar]
  6. Birket-Smith E. Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurol Scand. 1974;50(6):801–811. doi: 10.1111/j.1600-0404.1974.tb02820.x. [DOI] [PubMed] [Google Scholar]
  7. Brandon S., McClelland H. A., Protheroe C. A study of facial dyskinesia in a mental hospital population. Br J Psychiatry. 1971 Feb;118(543):171–184. doi: 10.1192/bjp.118.543.171. [DOI] [PubMed] [Google Scholar]
  8. Bucci L. The dyskenesias: a new therapeutic approach. Dis Nerv Syst. 1971 May;32(5):324–327. [PubMed] [Google Scholar]
  9. CARLSSON A., LINDQVIST M. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh) 1963;20:140–144. doi: 10.1111/j.1600-0773.1963.tb01730.x. [DOI] [PubMed] [Google Scholar]
  10. Calne D. B., Claveria L. E., Teychenne P. F., Haskayne L., Lodge-Patch I. C. Pimozide in tardive dyskinesia. Trans Am Neurol Assoc. 1974;99:166–170. [PubMed] [Google Scholar]
  11. Carruthers S. G. Persistent tardive dyskinesia. Br Med J. 1971 Sep 4;3(5774):572–572. doi: 10.1136/bmj.3.5774.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Casey D. E., Denney D. Letter: Dimethylaminoethanol in tardive dyskinesia. N Engl J Med. 1974 Oct 10;291(15):797–797. doi: 10.1056/nejm197410102911521. [DOI] [PubMed] [Google Scholar]
  13. Christensen E., Moller J. E., Faurbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand. 1970;46(1):14–23. doi: 10.1111/j.1600-0447.1970.tb02097.x. [DOI] [PubMed] [Google Scholar]
  14. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  15. Crane G. E. High doses of trifluperazine and tardive dyskinesia. Arch Neurol. 1970 Feb;22(2):176–180. doi: 10.1001/archneur.1970.00480200082009. [DOI] [PubMed] [Google Scholar]
  16. Crane G. E. More on amantadine in tardive dyskinesia. N Engl J Med. 1971 Nov;285(20):1150–1151. doi: 10.1056/NEJM197111112852025. [DOI] [PubMed] [Google Scholar]
  17. Crane G. E. Persistence of neurological symptoms due to neuroleptic drugs. Am J Psychiatry. 1971 Apr;127(10):1407–1410. doi: 10.1176/ajp.127.10.1407. [DOI] [PubMed] [Google Scholar]
  18. Crane G. E. Prevention and management of tardive dyskinesia. Am J Psychiatry. 1972 Oct;129(4):466–467. doi: 10.1176/ajp.129.4.466. [DOI] [PubMed] [Google Scholar]
  19. Crane G. E. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry. 1968 Feb;124(8 Suppl):40–48. doi: 10.1176/ajp.124.8S.40. [DOI] [PubMed] [Google Scholar]
  20. Crane G. E. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie. 1968 Mar-Apr;9(2):209–218. [PubMed] [Google Scholar]
  21. Crane G. E., Turek I. S., Kurland A. A. Failure of pyridoxine to reduce drug-induced dyskinesias. J Neurol Neurosurg Psychiatry. 1970 Aug;33(4):511–512. doi: 10.1136/jnnp.33.4.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. DRUCKMAN R., SEELINGER D., THULIN B. Chronic involuntary movements induced by phenothiazines. J Nerv Ment Dis. 1962 Jul;135:69–76. doi: 10.1097/00005053-196207000-00009. [DOI] [PubMed] [Google Scholar]
  23. Dalén P. Lithium therapy in Huntington's chorea and tardive dyskinesia. Lancet. 1973 Jan 13;1(7794):107–108. doi: 10.1016/s0140-6736(73)90510-2. [DOI] [PubMed] [Google Scholar]
  24. Decker B. L., Davis J. M., Jonowsky D. S., el-Yousef M. K., Sekerke H. J. Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med. 1971 Oct 7;285(15):860–860. doi: 10.1056/NEJM197110072851516. [DOI] [PubMed] [Google Scholar]
  25. Duvoisin R. C., Yahr M. D., Coté L. D. Pyridoxine reversal of L-dopa effects in Parkinsonism. Trans Am Neurol Assoc. 1969;94:81–84. [PubMed] [Google Scholar]
  26. Dynes J. B. Oral dyskinesias--occurrence and treatment. Dis Nerv Syst. 1970 Dec;31(12):854–859. [PubMed] [Google Scholar]
  27. EVANS J. H. PERSISTENT ORAL DYSKINESIA IN TREATMENT WITH PHENOTHIAZINE DERIVATIVES. Lancet. 1965 Feb 27;1(7383):458–460. doi: 10.1016/s0140-6736(65)91590-4. [DOI] [PubMed] [Google Scholar]
  28. Edwards H. The significance of brain damage in persistent oral dyskinesia. Br J Psychiatry. 1970 Mar;116(532):271–275. doi: 10.1192/bjp.116.532.271. [DOI] [PubMed] [Google Scholar]
  29. Eibergen R. D., Carlson K. R. Dyskinesias elicited by methamphetamine: susceptibility of former methadone-consuming monkeys. Science. 1975 Nov 7;190(4214):588–590. doi: 10.1126/science.810889. [DOI] [PubMed] [Google Scholar]
  30. Escobar J. I., Kemp K. F. Letter: Dimethylaminoethanol for tardive dyskinesia. N Engl J Med. 1975 Feb 6;292(6):317–318. doi: 10.1056/NEJM197502062920617. [DOI] [PubMed] [Google Scholar]
  31. FAURBYE A., RASCH P. J., PETERSEN P. B., BRANDBORG G., PAKKENBERG H. NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES. Acta Psychiatr Scand. 1964;40:10–27. doi: 10.1111/j.1600-0447.1964.tb05731.x. [DOI] [PubMed] [Google Scholar]
  32. Fann W. E., Davis J. M., Janowsky D. S. The prevalence of tardive dyskinesias in mental hospital patients. Dis Nerv Syst. 1972 Mar;33(3):182–186. [PubMed] [Google Scholar]
  33. Gardos G., Cole J. O. Letter: Papaverine for tardive dyskinesia? N Engl J Med. 1975 Jun 19;292(25):1355–1355. doi: 10.1056/NEJM197506192922521. [DOI] [PubMed] [Google Scholar]
  34. Gerlach J., Koppelhus P., Helweg E., Monrad A. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand. 1974;50(4):410–424. doi: 10.1111/j.1600-0447.1974.tb09706.x. [DOI] [PubMed] [Google Scholar]
  35. Gerlach J., Reisby N., Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia. 1974 Jan 9;34(1):21–35. doi: 10.1007/BF00421217. [DOI] [PubMed] [Google Scholar]
  36. Godwin-Austen R. B., Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J. 1971 Oct 2;4(5778):25–26. doi: 10.1136/bmj.4.5778.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Greenblatt D. L., Dominick J. R., Stotsky B. A., DiMascio A. Phenothiazine-induced dyskinesia in nursing-home patients. J Am Geriatr Soc. 1968 Jan;16(1):27–34. doi: 10.1111/j.1532-5415.1968.tb03966.x. [DOI] [PubMed] [Google Scholar]
  38. Guilleminault C., Tharp B. R., Cousin D. HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements. J Neurol Sci. 1973 Apr;18(4):435–441. doi: 10.1016/0022-510x(73)90137-8. [DOI] [PubMed] [Google Scholar]
  39. HUNTER R., EARL C. J., THRONICROFT S. AN APPARENTLY IRREVERSIBLE SYNDROME OF ABNORMAL MOVEMENTS FOLLOWING PHENOTHIAZINE MEDICATION. Proc R Soc Med. 1964 Aug;57:758–762. doi: 10.1177/003591576405700835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Henning M. Studies on the mode of action of alpha-methyldopa. Acta Physiol Scand Suppl. 1969;322:1–37. [PubMed] [Google Scholar]
  41. Hershon H. I., Kennedy P. F., McGuire R. J. Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br J Psychiatry. 1972 Jan;120(554):41–50. doi: 10.1192/bjp.120.554.41. [DOI] [PubMed] [Google Scholar]
  42. Hunter R., Blackwood W., Smith M. C., Cumings J. N. Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication. J Neurol Sci. 1968 Sep-Oct;7(2):263–273. doi: 10.1016/0022-510x(68)90148-2. [DOI] [PubMed] [Google Scholar]
  43. Jacobson G., Baldessarini R. J., Manschreck T. Tardive and withdrawal dyskinesia associated with haloperidol. Am J Psychiatry. 1974 Aug;131(8):910–913. doi: 10.1176/ajp.131.8.910. [DOI] [PubMed] [Google Scholar]
  44. Jameson H. D. Pyridoxine for levodopa-induced dystonia. JAMA. 1970 Mar 9;211(10):1700–1700. [PubMed] [Google Scholar]
  45. Janowsky D. S., el-Yousef M. K., Davis J. M., Sekerke H. J., Morris D. R., Decker B. Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism. N Engl J Med. 1972 Apr 6;286(14):785–785. doi: 10.1056/NEJM197204062861424. [DOI] [PubMed] [Google Scholar]
  46. Kazamatsuri H., Chien C. P., Cole J. O. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973 Apr;130(4):479–483. doi: 10.1176/ajp.130.4.479. [DOI] [PubMed] [Google Scholar]
  47. Kazamatsuri H., Chien C., Cole J. O. Therapeutic approaches to tardive dyskinesia. A review of the literature. Arch Gen Psychiatry. 1972 Oct;27(4):491–499. doi: 10.1001/archpsyc.1972.01750280059011. [DOI] [PubMed] [Google Scholar]
  48. Kazamatsuri H., Chien C., Cole J. O. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972 Jul;27(1):95–99. doi: 10.1001/archpsyc.1972.01750250081011. [DOI] [PubMed] [Google Scholar]
  49. Kazamatsuri H., Chien C., Cole J. O. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry. 1972 Jul;27(1):100–103. doi: 10.1001/archpsyc.1972.01750250086012. [DOI] [PubMed] [Google Scholar]
  50. Kazamatsuri H., Cole J. O. Treatment of tardive dyskinesia. 3. Clinical efficacy of a dopamine competing agent, methyldopa. Arch Gen Psychiatry. 1972 Dec;27(6):824–827. doi: 10.1001/archpsyc.1972.01750300086016. [DOI] [PubMed] [Google Scholar]
  51. Kennedy P. F., Hershon H. I., McGuire R. J. Extrapyramidal disorders after prolonged phenothiazine therapy. Br J Psychiatry. 1971 May;118(546):509–518. doi: 10.1192/bjp.118.546.509. [DOI] [PubMed] [Google Scholar]
  52. Klawans H. L., Bergen D., Bruyn G. W., Paulson G. W. Neuroleptic-induced tardiave dyskinesias in nonpsychotic patients. Arch Neurol. 1974 Apr;30(4):338–339. doi: 10.1001/archneur.1974.00490340066018. [DOI] [PubMed] [Google Scholar]
  53. Klawans H. L., Jr The pharmacology of tardive dyskinesias. Am J Psychiatry. 1973 Jan;130(1):82–86. doi: 10.1176/ajp.130.1.82. [DOI] [PubMed] [Google Scholar]
  54. Klawans H. L., Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974 Aug;37(8):941–947. doi: 10.1136/jnnp.37.8.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Letter: Deanol for tardive dyskinesia. N Engl J Med. 1975 Apr 24;292(17):926–927. doi: 10.1056/NEJM197504242921720. [DOI] [PubMed] [Google Scholar]
  56. Letter: Deanol for tardive dyskinesia. N Engl J Med. 1975 Apr 24;292(17):926–927. doi: 10.1056/NEJM197504242921720. [DOI] [PubMed] [Google Scholar]
  57. MacCallum W. A. Tetrabenazine for extra-pyramidal movement disorders. Br Med J. 1970 Mar 21;1(5698):760–760. doi: 10.1136/bmj.1.5698.760-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Mena I., Court J., Fuenzalida S., Papavasiliou P. S., Cotzias G. C. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med. 1970 Jan 1;282(1):5–10. doi: 10.1056/NEJM197001012820102. [DOI] [PubMed] [Google Scholar]
  59. Merren M. D. Amantadine in tardive dyskinesia. N Engl J Med. 1972 Feb 3;286(5):268–268. doi: 10.1056/nejm197202032860522. [DOI] [PubMed] [Google Scholar]
  60. Miller E. M. Letter: Deanol: a solution for tardive dyskinesia? N Engl J Med. 1974 Oct 10;291(15):796–797. doi: 10.1056/NEJM197410102911520. [DOI] [PubMed] [Google Scholar]
  61. Miller R. J., Hiley C. R. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature. 1974 Apr 12;248(449):596–597. doi: 10.1038/248596a0. [DOI] [PubMed] [Google Scholar]
  62. Pakkenberg H., Fog R. Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both. Arch Neurol. 1974 Nov;31(5):352–353. doi: 10.1001/archneur.1974.00490410100014. [DOI] [PubMed] [Google Scholar]
  63. Peters H. A., Daly R. F., Sato S. Reserpine for tardive dyskinesia. N Engl J Med. 1972 Jan 13;286(2):106–106. doi: 10.1056/nejm197201132860219. [DOI] [PubMed] [Google Scholar]
  64. Re' O. 2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Ther Res Clin Exp. 1974 Nov;16(11):1238–1242. [PubMed] [Google Scholar]
  65. Reda F. A., Scanlan J. M., Kemp K., Escobar J. I. Letter: Treatment of tardive dyskinesia with lithium carbonate. N Engl J Med. 1974 Oct 17;291(16):850–850. [PubMed] [Google Scholar]
  66. Roxburgh P. A. Treatment of persistent phenothiazine-induced oral dyskinesia. Br J Psychiatry. 1970 Mar;116(532):277–280. doi: 10.1192/bjp.116.532.277. [DOI] [PubMed] [Google Scholar]
  67. Rubovits R., Klawans H. L., Jr Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias. Arch Gen Psychiatry. 1972 Oct;27(4):502–507. doi: 10.1001/archpsyc.1972.01750280070012. [DOI] [PubMed] [Google Scholar]
  68. STOLZE R., ULE G. Die Bedeutung der Trigeminusdegeneration für die Sprachstörung bei der hereditären Ataxie. Nervenarzt. 1957 Jan 20;28(1):35–36. [PubMed] [Google Scholar]
  69. Sato S., Daly R., Peters H. Reserpine therapy of phenothiazine induced dyskinesia. Dis Nerv Syst. 1971 Oct;32(10):680–685. [PubMed] [Google Scholar]
  70. Schildkraut J. J., Schanberg S. M., Kopin I. J. The effects of lithium ion on H3-norepinephrine metabolism in brain. Life Sci. 1966 Aug;5(16):1479–1483. doi: 10.1016/0024-3205(66)90221-9. [DOI] [PubMed] [Google Scholar]
  71. Schmidt W. R., Jarcho L. W. Persistent dyskinesias following phenothiazine therapy. Report of five cases and a review of the literature. Arch Neurol. 1966 Apr;14(4):369–377. doi: 10.1001/archneur.1966.00470100025003. [DOI] [PubMed] [Google Scholar]
  72. Siede H., Müller H. F. Choreiform movements as side effects of phenothiazine medication in geriatric patients. J Am Geriatr Soc. 1967 Jun;15(6):517–522. doi: 10.1111/j.1532-5415.1967.tb01191.x. [DOI] [PubMed] [Google Scholar]
  73. Singer K., Cheng M. N. Thiopropazate hydrochloride in persistent dyskinesia. Br Med J. 1971 Oct 2;4(5778):22–25. doi: 10.1136/bmj.4.5778.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Singer K., Cheng M. N. Thiopropazate hydrochloride in persistent dyskinesia. Br Med J. 1971 Dec 4;4(5787):626–626. doi: 10.1136/bmj.4.5787.626-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Snyder S. H., Banerjee S. P., Yamamura H. I., Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science. 1974 Jun 21;184(4143):1243–1253. doi: 10.1126/science.184.4143.1243. [DOI] [PubMed] [Google Scholar]
  76. Snyder S., Greenberg D., Yamamura H. I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58–61. doi: 10.1001/archpsyc.1974.01760130040006. [DOI] [PubMed] [Google Scholar]
  77. Sutcher H. D., Underwood R. B., Beatty R. A., Sugar O. Orofacial dyskinesia. A dental dimension. JAMA. 1971 May 31;216(9):1459–1463. [PubMed] [Google Scholar]
  78. Tarsy D., Leopold N., Sax D. S. Physostigmine in choreiform movement disorders. Neurology. 1974 Jan;24(1):28–33. doi: 10.1212/wnl.24.1.28. [DOI] [PubMed] [Google Scholar]
  79. Turunen S., Achté K. A. The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy. Psychiatr Q. 1967;41(2):268–279. doi: 10.1007/BF01573344. [DOI] [PubMed] [Google Scholar]
  80. Vale S., Espejel M. A. Amantadine for dyskinesia tarda. N Engl J Med. 1971 Mar 25;284(12):673–673. doi: 10.1056/nejm197103252841216. [DOI] [PubMed] [Google Scholar]
  81. Villeneuve A., Böszörményi Z. Treatment of drug-induced dyskinesias. Lancet. 1970 Feb 14;1(7642):353–354. doi: 10.1016/s0140-6736(70)90724-5. [DOI] [PubMed] [Google Scholar]
  82. Vonvoigtlander P. F., Losey E. G., Triezenberg H. J. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther. 1975 Apr;193(1):88–94. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES